Sanofi sees higher earnings as blockbuster skin drug soars
![Photo: VIOLETA SANTOS MOURA/REUTERS / X07448](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13705198.ece/ALTERNATES/schema-16_9/doc7jknz1lqgi11dqin7cj8.jpg)
Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.